Latest Aztreonam impurity reference standards Requirements for Impurities in Drug Review Supplements

  Aztreonam is clinically indicated for the treatment of various infections caused by susceptible aerobic Gram-negative bacteria. It exerts a specific action against these bacteria by precisely inhibiting bacterial cell wall synthesis and remains stable against most β-lactamases. Consequently, it is a cornerstone therapeutic agent for moderate to severe Gram-negative bacterial infections.

  The synthesis of aztreonam is complex, involving multiple chemical reactions. Several critical steps, due to harsh reaction conditions, highly reactive reagents, and unstable intermediates, are particularly prone to introducing process-related impurities. Major pharmacopoeias, such as the USP, have clearly documented several known aztreonam impurities, including Aztreonam Open-ring Impurity, Desulfo Aztreonam Open-ring Impurity, and Aztreonam E-Isomer, and have established definitive standards for their limits.

  In response to the latest regulatory feedback for aztreonam drug development and registration, SZEB proudly supplies the following Aztreonam Impurity Reference Standards: Aztreonam Dimer Impurity, Aztreonam Open-ring Impurity, Desulfo Aztreonam Open-ring Impurity, and Aztreonam E-Isomer..